Immunophotonics, Inc. has announced the recruitment and the dosing of its first patient in a multinational clinical trial in the United Kingdom at the University College London. This multinational clinical trial sponsored by Immunophotonics will assess the safety and efficacy of its lead asset, IP-001, and is currently enrolling patients for treatment of colorectal cancer, non-small cell lung cancer, and soft tissue sarcoma in the United Kingdom, Switzerland, France, and Germany.  Read more: (Official Press Release)